You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

Drug Price Trends for ISOSORBIDE-HYDRALAZINE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for ISOSORBIDE-HYDRALAZINE

Average Pharmacy Cost for ISOSORBIDE-HYDRALAZINE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
ISOSORBIDE-HYDRALAZINE 20-37.5 MG TABLET 50742-0246-90 0.94420 EACH 2025-01-22
ISOSORBIDE-HYDRALAZINE 20-37.5 MG TABLET 52536-0006-09 0.94420 EACH 2025-01-22
ISOSORBIDE-HYDRALAZINE 20-37.5 MG TABLET 72319-0012-03 0.94420 EACH 2025-01-22
ISOSORBIDE-HYDRALAZINE 20-37.5 MG TABLET 50742-0246-90 0.97511 EACH 2024-12-18
ISOSORBIDE-HYDRALAZINE 20-37.5 MG TABLET 72319-0012-03 0.97511 EACH 2024-12-18
ISOSORBIDE-HYDRALAZINE 20-37.5 MG TABLET 52536-0006-09 0.97511 EACH 2024-12-18
ISOSORBIDE-HYDRALAZINE 20-37.5 MG TABLET 72319-0012-03 1.00831 EACH 2024-11-20
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Isosorbide Dinitrate and Hydralazine

Introduction

Isosorbide dinitrate and hydralazine, commonly known by the brand name BiDil, is a fixed-dose combination medication used primarily to treat heart failure in black patients. This analysis will delve into the market dynamics, pricing, and future projections for this medication.

Market Overview

The global market for hydralazine, a key component of the isosorbide dinitrate and hydralazine combination, is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.5% during the forecast period. This growth is driven by the increasing prevalence of hypertension and heart diseases, which affect a significant portion of the global population. According to the World Health Organization (WHO), approximately 1 billion people worldwide suffer from high blood pressure, making it a leading cause of death globally[3].

Indications and Usage

Isosorbide dinitrate and hydralazine are specifically indicated for the treatment of heart failure in black patients. This combination works by relaxing blood vessels, increasing blood and oxygen supply to the heart, and reducing the heart's workload. Each tablet contains 20 milligrams of isosorbide dinitrate and 37.5 milligrams of hydralazine, and the typical dosage is one tablet three times a day, adjustable by the doctor as needed[1].

Pricing and Cost-Effectiveness

The cost of isosorbide dinitrate and hydralazine can vary depending on the pharmacy and location. On average, a supply of 90 tablets (37.5 mg-20 mg) can cost between $264.53 and $330.31 for cash-paying customers. This price can be significantly reduced using discount cards or other patient assistance programs, although no specific patient assistance programs are currently available for this medication[2].

Studies have shown that the fixed-dose combination of isosorbide dinitrate and hydralazine is cost-effective. The African-American Heart Failure Trial (A-HeFT) demonstrated that this therapy reduced heart failure-related hospitalizations and total healthcare costs. With an average daily drug cost of $6.38, ISDN/HYD therapy was found to be dominant in terms of both reduced costs and improved outcomes over the trial duration[5].

Market Segments

The market for hydralazine and isosorbide dinitrate can be segmented based on several factors:

By Form

  • The tablet form is expected to grow significantly during the forecast period, as it is commonly used for treating hypertension and heart failure. Hydralazine is also available in injectable form for managing severe hypertension[3].

By Indication

  • The market is primarily classified into hypertension, congestive heart failure, and other indications. Hypertension is expected to drive significant growth due to the rising geriatric population and changes in lifestyle[3].

Competitive Landscape

The market for miscellaneous antihypertensive combinations, which includes isosorbide dinitrate and hydralazine, is competitive. However, BiDil holds a unique position due to its specific indication for heart failure in black patients. The absence of manufacturer promotions and patient assistance programs for this medication may affect its market share, but the cost-effectiveness and clinical benefits demonstrated in trials like A-HeFT support its continued use[2][5].

Future Projections

Given the rising prevalence of hypertension and heart diseases, the demand for isosorbide dinitrate and hydralazine is expected to increase. Here are some key projections:

  • Growth Rate: The global hydralazine market, including the combination with isosorbide dinitrate, is expected to grow at a CAGR of 3.5% during the forecast period[3].
  • Cost-Effectiveness: Long-term use of ISDN/HYD therapy is projected to maintain a favorable cost-effectiveness profile, with estimated costs per life-year ranging from $16,600 to $41,800 over different time horizons[5].
  • Market Expansion: The increasing geriatric population and changes in lifestyle are expected to drive the market growth, particularly in regions with high prevalence of hypertension and heart diseases.

Challenges and Opportunities

Challenges

  • Side Effects: Despite its benefits, the medication can cause serious side effects such as low blood pressure, headache, rash, and dizziness. Patients need to be closely monitored by healthcare professionals[3].
  • Cost: Although the medication is cost-effective in the long run, the initial cost can be a barrier for some patients, especially without patient assistance programs.

Opportunities

  • Growing Demand: The rising prevalence of hypertension and heart diseases presents a significant opportunity for growth.
  • Clinical Benefits: The proven clinical benefits and cost-effectiveness of ISDN/HYD therapy make it an attractive option for healthcare providers and patients.

Key Takeaways

  • Market Growth: The global market for hydralazine and isosorbide dinitrate is expected to grow at a CAGR of 3.5% driven by the increasing prevalence of hypertension and heart diseases.
  • Cost-Effectiveness: The medication has been shown to be cost-effective, reducing healthcare costs and improving clinical outcomes.
  • Specific Indication: BiDil is specifically indicated for heart failure in black patients, making it a unique offering in the market.
  • Future Projections: The demand for this medication is expected to increase, driven by demographic and lifestyle changes.

FAQs

Q: What is the primary indication for isosorbide dinitrate and hydralazine? A: The primary indication for isosorbide dinitrate and hydralazine is the treatment of heart failure in black patients.

Q: How does the combination of isosorbide dinitrate and hydralazine work? A: The combination works by relaxing blood vessels, increasing blood and oxygen supply to the heart, and reducing the heart's workload.

Q: What is the average cost of isosorbide dinitrate and hydralazine? A: The average cost for a supply of 90 tablets (37.5 mg-20 mg) can range from $264.53 to $330.31 for cash-paying customers.

Q: Is the medication cost-effective? A: Yes, studies have shown that the fixed-dose combination of isosorbide dinitrate and hydralazine is cost-effective, reducing healthcare costs and improving clinical outcomes.

Q: What are the potential side effects of isosorbide dinitrate and hydralazine? A: Potential side effects include blurred vision, confusion, dizziness, sweating, and unusual tiredness or weakness. Serious side effects can include fainting, fast or irregular heartbeat, and more rarely, heart problems and lupus-like syndrome[1].

Sources

  1. Mayo Clinic: Isosorbide dinitrate and hydralazine (oral route) - Mayo Clinic.
  2. Drugs.com: Hydralazine/isosorbide dinitrate Prices, Coupons, Copay Cards & Patient Assistance.
  3. Biospace: Global Hydralazine Market to Grow at a CAGR of 3.5% During Forecast Period - Emergen Research.
  4. Circulation: Hydralazine and Isosorbide Dinitrate in Heart Failure | Circulation.
  5. PubMed: Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine in the treatment of heart failure.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.